A 24-month Randomised Parallel Group Single-blinded Multi-centre Phase 1 Pilot Study of AADvac1 in Patients With Non Fluent Primary Progressive ... View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2017-2020

ABSTRACT

This study is a pilot trial evaluating the safety and immunogenicity of AADvac1 in patients with the non-fluent variant of Primary Progressive Aphasia. 50% of participants will receive the 40 µg dosage of AADvac1 and 50% of participants will receive the 160 µg dosage of AADvac1. No placebo is used. Detailed Description The non-fluent variant of Primary progressive Aphasia (nfvPPA) is a chronic progressive neurodegenerative disorder of the brain. Over the course of the disease, pathological proteins accumulate in the brain, damaging neurons, thus causing them to lose their connections and die. No treatments are currently available; symptomatic medications are used off-label in nfvPPA. AADvac1 is designed to raise antibodies against pathological tau protein (the primary constituent of neurofibrillary pathology, which is the underlying cause of disease in ~80% of nfvPPA cases). These antibodies are expected to prevent tau protein from aggregating, to facilitate the removal of tau protein aggregates and prevent the spreading of pathology, slowing or halting the progress of the disease. More... »

URL

https://clinicaltrials.gov/show/NCT03174886

Related SciGraph Publications

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3120", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "This study is a pilot trial evaluating the safety and immunogenicity of AADvac1 in patients with the non-fluent variant of Primary Progressive Aphasia. 50% of participants will receive the 40 \u00b5g dosage of AADvac1 and 50% of participants will receive the 160 \u00b5g dosage of AADvac1. No placebo is used.\n\nDetailed Description\nThe non-fluent variant of Primary progressive Aphasia (nfvPPA) is a chronic progressive neurodegenerative disorder of the brain. Over the course of the disease, pathological proteins accumulate in the brain, damaging neurons, thus causing them to lose their connections and die. No treatments are currently available; symptomatic medications are used off-label in nfvPPA. AADvac1 is designed to raise antibodies against pathological tau protein (the primary constituent of neurofibrillary pathology, which is the underlying cause of disease in ~80% of nfvPPA cases). These antibodies are expected to prevent tau protein from aggregating, to facilitate the removal of tau protein aggregates and prevent the spreading of pathology, slowing or halting the progress of the disease.", 
    "endDate": "2020-07-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT03174886", 
    "keywords": [
      "parallel group", 
      "multi-centre", 
      "pilot", 
      "patient", 
      "Primary progressive aphasia", 
      "pilot trial", 
      "safety", 
      "immunogenicity", 
      "variant", 
      "dosage", 
      "placebo", 
      "progressive neurodegenerative disorder", 
      "brain", 
      "disease", 
      "protein", 
      "damaging", 
      "connection", 
      "medication", 
      "label", 
      "antibody", 
      "tau protein", 
      "primary constituent", 
      "neurofibrillary pathology", 
      "aggregating", 
      "removal", 
      "protein aggregate", 
      "spreading", 
      "pathology", 
      "progress"
    ], 
    "name": "A 24-month Randomised Parallel Group Single-blinded Multi-centre Phase 1 Pilot Study of AADvac1 in Patients With Non Fluent Primary Progressive Aphasia", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT03174886"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:27", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00024.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.6582.9", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.410712.1", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.15474.33", 
        "type": "Organization"
      }
    ], 
    "startDate": "2017-07-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "https://doi.org/10.1016/s1474-4422(16)30331-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002260688"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/alzrt278", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042088002", 
          "https://doi.org/10.1186/alzrt278"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/alzrt277", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047897730", 
          "https://doi.org/10.1186/alzrt277"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT03174886"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT03174886'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT03174886'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT03174886'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT03174886'


 

This table displays all metadata directly associated to this object as RDF triples.

63 TRIPLES      16 PREDICATES      49 URIs      38 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT03174886 schema:about anzsrc-for:3120
2 schema:description This study is a pilot trial evaluating the safety and immunogenicity of AADvac1 in patients with the non-fluent variant of Primary Progressive Aphasia. 50% of participants will receive the 40 µg dosage of AADvac1 and 50% of participants will receive the 160 µg dosage of AADvac1. No placebo is used. Detailed Description The non-fluent variant of Primary progressive Aphasia (nfvPPA) is a chronic progressive neurodegenerative disorder of the brain. Over the course of the disease, pathological proteins accumulate in the brain, damaging neurons, thus causing them to lose their connections and die. No treatments are currently available; symptomatic medications are used off-label in nfvPPA. AADvac1 is designed to raise antibodies against pathological tau protein (the primary constituent of neurofibrillary pathology, which is the underlying cause of disease in ~80% of nfvPPA cases). These antibodies are expected to prevent tau protein from aggregating, to facilitate the removal of tau protein aggregates and prevent the spreading of pathology, slowing or halting the progress of the disease.
3 schema:endDate 2020-07-01T00:00:00Z
4 schema:keywords Primary progressive aphasia
5 aggregating
6 antibody
7 brain
8 connection
9 damaging
10 disease
11 dosage
12 immunogenicity
13 label
14 medication
15 multi-centre
16 neurofibrillary pathology
17 parallel group
18 pathology
19 patient
20 pilot
21 pilot trial
22 placebo
23 primary constituent
24 progress
25 progressive neurodegenerative disorder
26 protein
27 protein aggregate
28 removal
29 safety
30 spreading
31 tau protein
32 variant
33 schema:name A 24-month Randomised Parallel Group Single-blinded Multi-centre Phase 1 Pilot Study of AADvac1 in Patients With Non Fluent Primary Progressive Aphasia
34 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT03174886
35 schema:sdDatePublished 2019-03-07T15:27
36 schema:sdLicense https://scigraph.springernature.com/explorer/license/
37 schema:sdPublisher Nacfba49e81c948f69173986fdafa3162
38 schema:sponsor https://www.grid.ac/institutes/grid.15474.33
39 https://www.grid.ac/institutes/grid.410712.1
40 https://www.grid.ac/institutes/grid.6582.9
41 schema:startDate 2017-07-01T00:00:00Z
42 schema:subjectOf sg:pub.10.1186/alzrt277
43 sg:pub.10.1186/alzrt278
44 https://doi.org/10.1016/s1474-4422(16)30331-3
45 schema:url https://clinicaltrials.gov/show/NCT03174886
46 sgo:license sg:explorer/license/
47 sgo:sdDataset clinical_trials
48 rdf:type schema:MedicalStudy
49 Nacfba49e81c948f69173986fdafa3162 schema:name Springer Nature - SN SciGraph project
50 rdf:type schema:Organization
51 anzsrc-for:3120 schema:inDefinedTermSet anzsrc-for:
52 rdf:type schema:DefinedTerm
53 sg:pub.10.1186/alzrt277 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047897730
54 https://doi.org/10.1186/alzrt277
55 rdf:type schema:CreativeWork
56 sg:pub.10.1186/alzrt278 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042088002
57 https://doi.org/10.1186/alzrt278
58 rdf:type schema:CreativeWork
59 https://doi.org/10.1016/s1474-4422(16)30331-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002260688
60 rdf:type schema:CreativeWork
61 https://www.grid.ac/institutes/grid.15474.33 schema:Organization
62 https://www.grid.ac/institutes/grid.410712.1 schema:Organization
63 https://www.grid.ac/institutes/grid.6582.9 schema:Organization
 




Preview window. Press ESC to close (or click here)


...